Subgroup analysis for PFS and OS was performed according to PS (0–1/≥2), melanoma subtype (non‐acral cutaneous or unknown primary/acral or mucosal), BRAF genotype (V600E/V600K, R, or unspecified), AJCC stage (III or IV [M1a, M1b]/IV [M1c, M1d]), number of metastatic organ sites (1–2/≥3), and serum LDH at baseline (normal/elevated) (Figure S2). The gene discussed is BRAF; the disease is melanoma.